Fifth Addendum to Consulting Agreement between Avalon Pharmaceuticals, Inc. and Bradley G. Lorimier

Summary

Avalon Pharmaceuticals, Inc. and Bradley G. Lorimier have agreed to extend Lorimier's consulting contract until December 31, 2007, or until earlier termination as specified in the original agreement. Lorimier will continue to provide business development support and receive $10,000 per month. He remains bound by the confidentiality, invention assignment, and non-competition terms from the original agreement, which otherwise remains in effect.

EX-10.14F 3 w51513exv10w14f.htm EX-10.14F exv10w14f

Exhibit 10.14F

Fifth Addendum to Consulting Agreement
Dated February 1, 2000

This Fifth Addendum is made by and between Avalon Pharmaceuticals, Inc. (formerly Therapeutic Genomics, Inc.) a Delaware corporation, located at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“AVALON”), and Bradley G. Lorimier, an individual with an address at 7807 Fox Gate Court, Bethesda, MD 20817 (“CONSULTANT”).

In exchange for Consultant’s commitment to provide additional support to AVALON’S business development efforts, AVALON agrees to extend CONSULTANT’S contract term until December 31, 2007, or until terminated as set forth in section 6 of the February 1, 2000 Agreement.

CONSULTANT’S compensation will be $10,000 per month.

CONSULTANT acknowledges continuing to be bound by the terms and conditions of the agreement entitled “Confidentiality, Assignment of Inventions and Non-Competition Agreement” (Exhibit B) dated February 1, 2000.

CONSULTANT acknowledges that all other terms and conditions of the February 1, 2000 agreement are in full force and effect during the term of this extension.

READ, AGREED AND ACCEPTED:

Signed for and on behalf of


AVALON PHARMACEUTICALS, INC.		BRADLEY G. LORIMIER

By:	/s/ Kenneth C. Carter, Ph.D.	By:	/s/ Bradley G. Lorimier

Name:	Kenneth C. Carter, Ph.D	Date:	January 5, 2007
Title:	CEO & President
Date:	January 5, 2007